HER2 Targeting Era Of Colorectal Cancer Begins

OncoPharm
26/01/2023 10 min
HER2 Targeting Era Of Colorectal Cancer Begins

Listen "HER2 Targeting Era Of Colorectal Cancer Begins"

Descargar episodio Ver en sitio original

Episode Synopsis

Tucatinib's FDA-approval (with trastuzumab) for HER2 amplified metastatic colorectal cancer launches a new era of targeted therapy in colorectal cancer.

Targeting HER2 (amplified in ~3-5% of advanced colorectal cancers) in colorectal cancer will likely evolve over the coming years, so a brief history on how it has evolved so far may be helpful.
© 2003-2026 ZARZA | AHEAD OF OUR TIME
privacy policy
In God we trust In God we trust
PreSales Questions? Click Here
or call our toll-free line at +1-888-5002068 Miami, Florida, USA